Usefulness of factor II and factor X as therapeutic markers in patients under chronic warfarin therapy

被引:10
作者
Costa, I. M. [1 ]
Serralheiro, A. I. [2 ]
Rodrigues, M. [2 ]
Alves, G. [3 ]
Falcao, A. C. [1 ,2 ]
机构
[1] Univ Coimbra, Fac Pharm, Dept Pharmacol, P-3000548 Coimbra, Portugal
[2] Univ Coimbra, Ctr Neurosci & Cell Biol CNC, P-3004517 Coimbra, Portugal
[3] Univ Beira Interior, Fac Hlth Sci, Hlth Sci Res Ctr CICS, P-6200506 Covilha, Portugal
关键词
Warfarin therapy; Clotting factors; Anticoagulant response markers; INTERNATIONAL NORMALIZED RATIO; ORAL ANTICOAGULATION; FACTOR-VII; PHARMACODYNAMICS; PLASMA;
D O I
10.1016/j.biopha.2009.09.020
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Oral anticoagulation with warfarin is a widely used form of treatment for an increasing number of medical conditions. Nevertheless, appropriate therapeutic monitoring and dosage readjustments should be carried out in order to ensure its safety and efficacy. Although prothrombin time (usually expressed as International normalized ratio [INR]) is the most common warfarin response marker, clotting factors (namely factors II and X) are also indicated as alternative anticoagulant effect markers. In this paper, we examine the relationship between these warfarin response markers using information obtained from eighty 80 patients undergoing long-term warfarin therapy. Within the usual INR therapeutic range (2.0-3.5), a moderate inverse correlation between INR and both clotting factors II and X was observed. However, for INR values above 3.5, a non-proportional relationship were found between INR and both response markers. Therefore, it can be concluded that below critical clotting factor concentrations (20.6% and 15.6% of factors II and X activity, respectively), time required for clot formation becomes non-proportional and haemostasis will be jeopardised. (C) 2009 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:130 / 132
页数:3
相关论文
共 18 条
[1]  
AIACH M, 1982, THROMB HAEMOSTASIS, V47, P69
[2]  
BANNINGER H, 1994, BIOCHEM J, V298, P157
[3]   Anticoagulation with warfarin in infants and children [J].
Buck, ML .
ANNALS OF PHARMACOTHERAPY, 1996, 30 (11) :1316-1322
[4]  
CARR ME, 1988, THROMB HAEMOSTASIS, V59, P535
[5]   INTERRELATIONSHIP AMONG INDIVIDUAL VITAMIN K-DEPENDENT CLOTTING FACTORS AT DIFFERENT LEVELS OF ANTICOAGULATION [J].
CHAN, E ;
AARONS, L ;
SERLIN, M ;
BRECKENRIDGE, A ;
ROWLAND, M .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 24 (05) :621-625
[6]   Therapeutic monitoring of warfarin: The appropriate response marker [J].
Costa, IM ;
Soares, PJ ;
Afonso, M ;
Ratado, P ;
Lanao, JM ;
Falcao, AC .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2000, 52 (11) :1405-1410
[8]  
Hoppensteadt DA, 1997, CLIN CHEM, V43, P1786
[9]   MONITORING WARFARIN THERAPY WITH THE INTERNATIONAL NORMALIZED RATIO [J].
HOWARD, PA .
ANNALS OF PHARMACOTHERAPY, 1994, 28 (02) :242-244
[10]   Pharmacokinetic optimisation of the treatment of deep vein thrombosis [J].
Iorio, A ;
Agnelli, G .
CLINICAL PHARMACOKINETICS, 1997, 32 (02) :145-172